Activity Provided By:

Postgraduate Institute for Medicine and PlatformQ Health Education, LLC.

Metastatic HER2-Positive Disease: Overcoming HER2 Resistance

Overview / Abstract:	Target Audience This activity is intended for medical oncologists, surgeons, pathologists, oncology nurses, physician assistants, oncology pharmacists, and other clinicians involved in the management of patients with HER2+ breast cancer. Learning Objectives At the conclusion of this activity, participants will be able to: Evaluate therapeutic options for the HER2 blockade in the first-line setting for HER-positive metastatic breast cancer (MBC) Compare and contrast safety and efficacy data of the second-line and beyond for HER2-positive MBC Evaluate how novel HER2-targeted treatment options with improved safety profiles can be incorporated as second-line and beyond options in the management of MBC Assess the therapeutic implications of ongoing clinical trials involving emerging agents for advanced HER2-positive disease
Expiration	Jun 23, 2021
Discipline(s)	Nursing CNE, Physician CME
Format	Online
Credits / Hours	1.0 AMA PRA Category 1 Credit(s)™
Accreditation	ACCME
Presenters / Authors / Faculty	Faculty Ann Partridge, MD, MPH Professor of Medicine Harvard Medical School Vice Chair, Medical Oncology Director, Adult Survivorship Program Director, Program for Young Women with Breast Cancer Dana-Farber Cancer Institute Adam Brufsky, MD, PhD Professor of Medicine; Associate Chief, Division of Hematology-Oncology; Co-Director, Comprehensive Breast Cancer Program Magee Women's Hospital UPMC Hillman Cancer Center University of Pittsburgh
Sponsors / Supporters / Grant Providers	Daiichi Sankyo, Inc., Seattle Genetics, Inc.,AstraZeneca
Keywords / Search Terms	Relias LLC FREE CME., Relias LLC., Breast Cancer Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map